

96. A composition according to claim 95 comprising a mixture of said first polypeptides.

97. A composition according to claim 95, further comprising a second isolated polypeptide that is different from the first polypeptide and that:

(a) has an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:11, and SEQ ID NO:12;

(b) has at least a portion of an amino acid sequence as described in (a) above and has an epitope in common therewith; or

(c) is a modified form of a polypeptide as described in (a) or (b) above, but has at least one epitope in common therewith.

98. A composition according to claim 97, comprising a mixture of said second polypeptides or a mixture of said first and second polypeptides.

99. A composition according to claim 97, wherein the first and second polypeptide are covalently linked in the form of a heterodimer.

103 conjugate?

100. A composition according to claim 97, wherein said composition has a stimulation index of at least approximately 4.0 or a positivity index of at least approximately 250, wherein the stimulation index is defined as the ratio of measured proliferation of T cells and antigen presenting cells from a responding individual when exposed to antigen to the measured proliferation of said cells in the absence of antigen, and wherein the positivity index is defined as the average stimulation index of a population of responding individuals tested multiplied by the percentage of individuals in the population exhibiting a positive response.

Part C3

101. An isolated polypeptide that:
- (a) has an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:16;
 - (b) has at least a part of a sequence as described in (a) above and has an epitope in common therewith; or
 - (c) is a modified form of a polypeptide as described in (a) or (b) above, but has at least one epitope in common therewith.

102. A polypeptide according claim 101, wherein the polypeptide has a stimulation index of at least approximately 4.0 or a positivity index of at least approximately 250, wherein the stimulation index is defined as the ratio of measured proliferation of T cells and antigen presenting cells from a responding individual when exposed to antigen to the measured proliferation of said cells in the absence of antigen, and wherein the positivity index is defined as the average stimulation index of a population of responding individuals tested multiplies by the percentage of individuals in the population exhibiting a positive response.

103. A polypeptide according to claim 101, produced recombinantly.

104. A polypeptide according to claim 101, produced by chemical synthesis.

105. A method of treating sensitivity to a cat protein allergen in a subject sensitive to the allergen, comprising administering to the subject the composition of claim 95.

106. A method of treating sensitivity to a cat protein allergen in a subject sensitive to the allergen, comprising administering to the subject the composition of claim 97.

B1
cont.
005760-132300